Atkinson Joseph H, Kremer Edwin F, Risch Samuel C, Janowsky David S
Department of Psychiatry (V-116), Veterans Administration Medical Center, 3350 La Jolla Village Drive, San Diego, CA 92161, U.S.A. Department of Psychiatry (M-003), University of California San Diego, School of Medicine, La Jolla, CA 92093 U.S.A.
Pain. 1986 Apr;25(1):23-34. doi: 10.1016/0304-3959(86)90005-9.
To assess the behavior of two putative neuroendocrine markers of depression in chronic pain, the authors determined plasma cortisol and prolactin concentrations before and after dexamethasone in 52 hospitalized male chronic pain patients. Their psychiatric diagnoses by Research Diagnostic Criteria (RDC) were: major depression (N = 24; 44.2%), minor depression (N = 10; 19.2%), another RDC diagnosis (N = 7; 13.5%) and not mentally ill (N = 12; 21.6%). Failure to suppress cortisol after dexamethasone (a positive DST) occurred in 43.5% of those with major depression, 20% of those with minor depression, 42.8% of those with other psychiatric diagnoses and in 8.3% of patients without a psychiatric disorder. The frequency of non-suppression was significantly different only for patients with major depression compared to those without diagnosable psychiatric disorder. Mean basal cortisol concentrations at 08.00, 16.00 and 23.00 h did not differ among psychiatric diagnostic groups of pain patients, or between these groups and healthy volunteers. Levels of prolactin, but not cortisol, were significantly correlated with the severity of mood disturbances. These findings suggest strategies using multiple endocrine markers to distinguish pain from depression should be explored.
为评估慢性疼痛中两种假定的抑郁症神经内分泌标志物的表现,作者测定了52名住院男性慢性疼痛患者在服用地塞米松前后的血浆皮质醇和催乳素浓度。根据研究诊断标准(RDC),他们的精神科诊断结果为:重度抑郁症(N = 24;44.2%)、轻度抑郁症(N = 10;19.2%)、其他RDC诊断(N = 7;13.5%)以及无精神疾病(N = 12;21.6%)。地塞米松后皮质醇未被抑制(地塞米松抑制试验阳性)的情况在43.5%的重度抑郁症患者、20%的轻度抑郁症患者、42.8%的其他精神科诊断患者以及8.3%无精神疾病的患者中出现。仅重度抑郁症患者与无精神疾病诊断的患者相比,未抑制的频率有显著差异。疼痛患者的精神科诊断组之间以及这些组与健康志愿者之间,在08:00、16:00和23:00时的平均基础皮质醇浓度无差异。催乳素水平而非皮质醇水平与情绪障碍的严重程度显著相关。这些发现表明,应探索使用多种内分泌标志物来区分疼痛和抑郁症的策略。